JP2015515462A5 - - Google Patents

Download PDF

Info

Publication number
JP2015515462A5
JP2015515462A5 JP2015501731A JP2015501731A JP2015515462A5 JP 2015515462 A5 JP2015515462 A5 JP 2015515462A5 JP 2015501731 A JP2015501731 A JP 2015501731A JP 2015501731 A JP2015501731 A JP 2015501731A JP 2015515462 A5 JP2015515462 A5 JP 2015515462A5
Authority
JP
Japan
Prior art keywords
blood
pegylated
composition
subject
albumin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015501731A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015515462A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/030355 external-priority patent/WO2013142135A1/en
Publication of JP2015515462A publication Critical patent/JP2015515462A/ja
Publication of JP2015515462A5 publication Critical patent/JP2015515462A5/ja
Pending legal-status Critical Current

Links

JP2015501731A 2012-03-20 2013-03-12 輸血の有効性を高める方法 Pending JP2015515462A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261613105P 2012-03-20 2012-03-20
US61/613,105 2012-03-20
PCT/US2013/030355 WO2013142135A1 (en) 2012-03-20 2013-03-12 Method of enhancing efficacy of blood transfusions

Publications (2)

Publication Number Publication Date
JP2015515462A JP2015515462A (ja) 2015-05-28
JP2015515462A5 true JP2015515462A5 (enExample) 2016-04-21

Family

ID=49223191

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015501731A Pending JP2015515462A (ja) 2012-03-20 2013-03-12 輸血の有効性を高める方法

Country Status (10)

Country Link
US (2) US8859499B2 (enExample)
EP (1) EP2827887A4 (enExample)
JP (1) JP2015515462A (enExample)
BR (1) BR112014023200A2 (enExample)
CL (1) CL2014002464A1 (enExample)
HK (1) HK1204267A1 (enExample)
IN (1) IN2014MN02089A (enExample)
MX (1) MX2014011186A (enExample)
WO (1) WO2013142135A1 (enExample)
ZA (1) ZA201407616B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160208011A1 (en) 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
WO2017120461A1 (en) 2016-01-08 2017-07-13 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US10487148B2 (en) 2010-01-28 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated impairments
US9161968B2 (en) 2011-04-08 2015-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
BR112014023200A2 (pt) 2012-03-20 2018-09-18 Albert Einstein College Of Medicine Of Yeshiva University uso de uma composição
EA035336B1 (ru) * 2013-12-09 2020-05-29 Зе Боард Оф Трастиз Оф Зе Леланд Стэнфорд Джуниор Юниверсити Способ лечения связанного со старением когнитивного расстройства или заболевания
US10905779B2 (en) 2013-12-09 2021-02-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening human blood products comprising plasma using immunocompromised rodent models
US20170333566A1 (en) * 2014-11-14 2017-11-23 Aima Biotech Conjugated Proteins
US20170258937A1 (en) * 2014-11-25 2017-09-14 Nanobiotix Pharmaceutical composition, preparation and uses thereof
EP3096160B1 (en) * 2015-05-20 2020-02-26 Veoneer Sweden AB An fmcw vehicle radar system
HK1246160A1 (zh) 2015-05-28 2018-09-07 Nanobiotix 用作治疗性疫苗的纳米粒子
AU2016279804B2 (en) 2015-06-15 2019-03-07 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated conditions
WO2017083281A1 (en) * 2015-11-09 2017-05-18 Albert Einstein College Of Medicine, Inc. Method of ameliorating side effects of sickle cell disease treatments
WO2017103914A1 (en) * 2015-12-17 2017-06-22 Regentis Biomaterials Ltd. Ready for use organic solvent free compositions comprising protein-polymer conjugates and uses thereof
WO2017189919A2 (en) 2016-04-28 2017-11-02 Alkahest, Inc. Blood plasma and plasma fractions as therapy for tumor growth and progression
US10525107B2 (en) 2016-08-18 2020-01-07 Alkahest, Inc. Blood plasma fractions as a treatment for aging-associated cognitive disorders
US11040068B2 (en) 2017-04-26 2021-06-22 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
UA127828C2 (uk) 2017-04-26 2024-01-17 Алкахест, Інк. Спосіб застосування фракції білків плазми крові для лікування когнітивних порушень
WO2019018403A1 (en) 2017-07-18 2019-01-24 Virtech Bio, Llc BLOOD SUBSTITUTES COMPRISING HEMOGLOBIN AND METHODS OF MAKING
CA3115308A1 (en) 2018-10-26 2020-04-30 Alkahest, Inc. Use of plasma and plasma fractions for improvement of pain, wound healing, and postoperative recovery
JP7773169B2 (ja) * 2021-02-24 2025-11-19 学校法人 中央大学 ポリオキサゾリン結合アルブミン、人工血漿増量剤及び出血ショックの蘇生液

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267269A (en) * 1980-02-05 1981-05-12 Baxter Travenol Laboratories, Inc. Red cell storage solution
JPS56139419A (en) * 1980-03-31 1981-10-30 Kuraray Co Ltd Erythrocytic preservative and erythrocytic pharmaceutical for preservation
AU752037B2 (en) * 1997-09-26 2002-09-05 Uab Research Foundation Reduced antigenic cells and uses therefor
DE69913716T2 (de) * 1998-09-25 2004-10-07 Oklahoma Med Res Found Hemmung der sichelbildung von erythrozyten mittels n-l-alpha-aspartyl-l-phenylalanine 1-methylester
US6251927B1 (en) * 1999-04-20 2001-06-26 Medinox, Inc. Methods for treatment of sickle cell anemia
US6875423B1 (en) * 1999-09-21 2005-04-05 Marcos Intaglietta Methods for increasing peripheral blood circulation
JP5099951B2 (ja) * 1999-11-12 2012-12-19 バクスター・インターナショナル・インコーポレイテッド 副作用が減少されたヘモグロビン組成物
US6811778B2 (en) * 2001-09-10 2004-11-02 Biopure Corporation Method for improving oxygen transport by stored red blood cells
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
US7144989B2 (en) * 2002-03-25 2006-12-05 Albert Einstein College Of Medicine Of Yeshiva University Pegylated non-hypertensive hemoglobins, methods of preparing same, and uses thereof
US7521174B2 (en) * 2003-12-05 2009-04-21 Albert Einstein College Of Medicine Of Yeshiva University Universal red blood cells, methods of preparing same, and uses thereof
US20080125432A1 (en) * 2004-12-01 2008-05-29 Devgen Nv 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family
WO2007058678A2 (en) * 2005-06-10 2007-05-24 Albert Einstein College Of Medicine Of Yeshiva University Uses of pegylated albumin
WO2006135740A1 (en) 2005-06-10 2006-12-21 Albert Einstein College Of Medicine Of Yeshiva University Pegylated hemoglobin and albumin and uses thereof
EP2391341A4 (en) * 2009-01-30 2012-05-09 Cuthbert O Simpkins REVIVAL LIQUID
WO2010117423A2 (en) * 2009-03-31 2010-10-14 Duke University A METHOD FOR TREATING A PATIENT HAVING OR AT RISK FOR DEVELOPING A DISORDER ASSOCIATED WITH DECREASED EXPRESSION OF ß2 ADRENERGIC RECEPTORS OR NEED FOR INCREASED ß2 ADRENERGIC RECEPTOR ACTIVITY
ES2966234T3 (es) * 2009-06-09 2024-04-18 Prolong Pharmaceuticals Llc Composiciones de hemoglobina
US20110189166A1 (en) * 2010-01-29 2011-08-04 John Boucher Methods of treating hemorheologic abnormalities in mammals
WO2011106086A1 (en) * 2010-02-25 2011-09-01 Albert Einstein College Of Medicine Of Yeshiva University Pegylated albumin polymers and uses thereof
BR112014023200A2 (pt) 2012-03-20 2018-09-18 Albert Einstein College Of Medicine Of Yeshiva University uso de uma composição
US20170333566A1 (en) 2014-11-14 2017-11-23 Aima Biotech Conjugated Proteins

Similar Documents

Publication Publication Date Title
JP2015515462A5 (enExample)
Li et al. Scaffold-facilitated locomotor improvement post complete spinal cord injury: Motor axon regeneration versus endogenous neuronal relay formation
JP2014520142A5 (enExample)
IL294463A (en) Methods for treating or preventing eye conditions
FI3227675T3 (fi) Aktiviini-actrii-antagonisteja ja niiden käyttöjä myelodysplastisen oireyhtymän hoitamiseksi
JP2011088927A5 (enExample)
NZ592837A (en) Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
CN102406205B (zh) 牡蛎多糖果汁饮料
JP2017505761A5 (enExample)
JP2017532343A5 (enExample)
RU2017116973A (ru) Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса
MX387845B (es) Polímeros enlazados al proton para administracion oral.
Lieder et al. Cardioprotection by post-conditioning with exogenous triiodothyronine in isolated perfused rat hearts and isolated adult rat cardiomyocytes
RU2018123666A (ru) Способ лечения рака у млекопитающего, включая человека, с примененим деплеции метионина и аспарагина
JP2017522288A5 (enExample)
JP2016513523A5 (enExample)
WO2012012388A3 (en) Therapeutic protein compositions having reduced immunogenicity and/or improved efficacy
JP2015532293A5 (ja) 糖尿病患者における心不全の治療用組成物
JP2017525704A5 (enExample)
Schmidt et al. Remote ischemic conditioning: the cardiologist's perspective
JP2005511504A5 (enExample)
Kumar et al. Horn cancer in bovines and its management
WO2012075244A3 (en) Use of hemoglobin effectors to increase the bioavailability of therapeutic gases
EP2525819A4 (en) IMMUNOTHERAPY COMPOSITIONS AND TREATMENT PROCEDURES
JP2014517038A5 (enExample)